Akebia Therapeutics Priced, Nasdaq: AKBA
Biotech developing a breakthrough anemia treatment with a once-daily oral dose.
Industry: Health Care
First Day Return: +57.1%
Industry: Health Care
AKBA
Biotech developing a breakthrough anemia treatment with a once-daily oral dose.
| IPO Data | |
|---|---|
| IPO File Date | 02/14/2014 |
| Offer Price | $17.00 |
| Price Range $14.00 - $17.00 | |
| Offer Shares (mm) | 5.9 |
| Deal Size ($mm) | $100 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 03/19/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $100 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2007 |
| Employees at IPO | 28 |
| Website www.akebia.com | |
IPO News for Akebia Therapeutics
Akebia Therapeutics (AKBA) Performance
